vTv Therapeutics (NASDAQ:VTVT) announced its earnings results on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06, Fidelity Earnings reports. The firm had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $2.06 million.
vTv Therapeutics stock traded down $0.01 during midday trading on Friday, reaching $2.63. 236,789 shares of the stock traded hands, compared to its average volume of 1,499,863. vTv Therapeutics has a 12-month low of $0.65 and a 12-month high of $8.40. The stock has a market capitalization of $90.48 million, a price-to-earnings ratio of -1.57 and a beta of -3.71.
In other news, major shareholder Ronald O. Perelman bought 1,879,699 shares of the stock in a transaction that occurred on Thursday, September 27th. The stock was bought at an average cost of $1.33 per share, for a total transaction of $2,499,999.67. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have purchased a total of 5,644,097 shares of company stock valued at $7,504,999 over the last 90 days. 2.00% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This report was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://sportsperspectives.com/2018/11/09/vtv-therapeutics-vtvt-announces-earnings-results-beats-estimates-by-0-06-eps.html.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Further Reading: Diversification For Individual Investors
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.